NYSE: GKOS | Healthcare / Medical Devices & Instruments / USA |
93.95 | +2.20 | +2.40% | Vol 30.71K | 1Y Perf 168.34% |
Apr 23rd, 2021 11:00 DELAYED |
BID | 93.89 | ASK | 94.23 | ||
Open | 92.19 | Previous Close | 91.75 | ||
Pre-Market | - | After-Market | - | ||
- -% | - - |
Target Price | 79.22 | Analyst Rating | Hold 2.67 | |
Potential % | -15.84 | Finscreener Ranking | ★★★ 50.03 | |
Insiders Trans % 3/6/12 mo. | -100/-100/-100 | Value Ranking | ★★★+ 53.80 | |
Insiders Value % 3/6/12 mo. | -100/-100/-100 | Growth Ranking | ★★ 45.21 | |
Insiders Shares Cnt. % 3/6/12 mo. | -100/-100/-100 | Income Ranking | — - | |
Market Cap | 4.30B | Earnings Rating | Strong Buy | |
Price Range Ratio 52W % | 92.22 | Earnings Date | 5th May 2021 |
Today's Price Range 92.1994.22 | 52W Range 34.1099.00 | 5 Year PE Ratio Range -1 992.00437.40 |
Summary:
Buy
Technical Indicators: | Neutral |
Moving Averages: | Strong Buy |
Performance | |||
---|---|---|---|
1 Week | 7.92% | ||
1 Month | 8.80% | ||
3 Months | 5.25% | ||
6 Months | 57.51% | ||
1 Year | 168.34% | ||
3 Years | 202.71% | ||
5 Years | 397.29% | ||
10 Years | - |
Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
ROE (5Y Avg) | -7.09 | |||
ROE last 12 Months | -17.19 | |||
ROA (5Y Avg) | -2.37 | |||
ROA last 12 Months | -12.69 | |||
ROC (5Y Avg) | -3.37 | |||
ROC last 12 Months | -11.44 | |||
Return on invested Capital Q | -0.72 | |||
Return on invested Capital Y | -13.02 | |||
Assets Turnover | 0.20 | |||
Receivables Turnover | 4.20 |
Valuation | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
-31.40 | ||||
5.83 | ||||
22.68 | ||||
86.40 | ||||
-242.70 | ||||
-0.52 | ||||
15.98 | ||||
14.58 | ||||
3.76B | ||||
Forward PE | -126.89 | |||
PEG | 13.48 |
Financial Strength | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
8.90 | ||||
9.40 | ||||
0.29 | ||||
0.41 | ||||
-8.40 | ||||
Leverage Ratio | 1.50 |
Profitability | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
59.20 | ||||
-63.70 | ||||
-49.70 | ||||
-16.60 | ||||
-36.94 |
Revenue | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
169.62M | ||||
3.70 | ||||
13.04 | ||||
23.81 |
Dividends | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
- | ||||
- | ||||
- | ||||
- | ||||
Payout ratio | - |
Earnings History | Estimate | Reported | Surprise % |
---|---|---|---|
Q04 2020 | -0.32 | -0.02 | 93.75 |
Q03 2020 | -0.46 | -0.09 | 80.43 |
Q02 2020 | -0.78 | -0.61 | 21.79 |
Q01 2020 | -0.35 | -0.44 | -25.71 |
Q04 2019 | -0.17 | -0.06 | 64.71 |
Q03 2019 | -0.17 | -0.10 | 41.18 |
Q02 2019 | -0.10 | -0.11 | -10.00 |
Q01 2019 | -0.12 | -0.04 | 66.67 |
Earnings Per End | Estimate | Revision % | Trend |
---|---|---|---|
3/2021 QR | -0.30 | 18.92 | Positive |
6/2021 QR | -0.30 | 9.09 | Positive |
12/2021 FY | -1.06 | 3.64 | Positive |
12/2022 FY | -0.67 | 5.63 | Positive |
Next Report Date | 5th May 2021 |
Estimated EPS Next Report | -0.30 |
Estimates Count | 7 |
EPS Growth Next 5 Years % | - |
Volume Overview | |
---|---|
Volume | 30.71K |
Shares Outstanding | 45.79M |
Trades Count | 601 |
Dollar Volume | 39.70M |
Avg. Volume | 420.23K |
Avg. Weekly Volume | 278.03K |
Avg. Monthly Volume | 399.12K |
Avg. Quarterly Volume | 400.64K |
Glaukos Corporation (NYSE: GKOS) stock closed at 91.75 per share at the end of the most recent trading day (a 1.3% change compared to the prior day closing price) with a volume of 260.18K shares and market capitalization of 4.30B. Is a component of indices and it is traded on NYSE exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 600 people. Glaukos Corporation CEO is Thomas W. Burns.
The one-year performance of Glaukos Corporation stock is 168.34%, while year-to-date (YTD) performance is 21.91%. GKOS stock has a five-year performance of 397.29%. Its 52-week range is between 34.1 and 99, which gives GKOS stock a 52-week price range ratio of 92.22%
Glaukos Corporation currently has a PE ratio of -31.40, a price-to-book (PB) ratio of 5.83, a price-to-sale (PS) ratio of 22.68, a price to cashflow ratio of 86.40, a PEG ratio of 2.32, a ROA of -12.69%, a ROC of -11.44% and a ROE of -17.19%. The company’s profit margin is -36.94%, its EBITDA margin is -49.70%, and its revenue ttm is $169.62 Million , which makes it $3.70 revenue per share.
Of the last four earnings reports from Glaukos Corporation, there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.30 for the next earnings report. Glaukos Corporation’s next earnings report date is 05th May 2021.
The consensus rating of Wall Street analysts for Glaukos Corporation is Hold (2.67), with a target price of $79.22, which is -15.84% compared to the current price. The earnings rating for Glaukos Corporation stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Glaukos Corporation has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Glaukos Corporation has a Buy technical analysis rating based on Technical Indicators (ADX : 13.85, ATR14 : 3.83, CCI20 : 269.96, Chaikin Money Flow : 0.02, MACD : -0.54, Money Flow Index : 52.51, ROC : 12.25, RSI : 58.43, STOCH (14,3) : 90.51, STOCH RSI : 1.00, UO : 61.68, Williams %R : -9.49), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Glaukos Corporation in the last 12-months were: Chris M. Calcaterra (Option Excercise at a value of $996 276), Chris M. Calcaterra (Sold 60 417 shares of value $5 339 776 ), Joseph E. Gilliam (Option Excercise at a value of $728 350), Joseph E. Gilliam (Sold 18 750 shares of value $1 767 336 ), Thomas W. Burns (Option Excercise at a value of $825 397), Thomas W. Burns (Sold 207 847 shares of value $8 152 748 ), William J. Link (Option Excercise at a value of $1 243 100), William J. Link (Sold 50 000 shares of value $3 398 322 )
Analyst Ratings | Current | 1 M ago | 3 M ago |
---|---|---|---|
Strong Buy | |||
Moderate Buy | |||
Hold | |||
Moderate Sell | |||
Strong Sell | |||
Summary Rating | Hold | Hold | Hold |
Glaukos Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. Its product pipeline also consists of an iStent SA trabecular micro-bypass system, a two-stent product that is slightly wider than the iStent Inject and uses a different auto-injection inserter designed for use in a standalone procedure.
CEO: Thomas W. Burns
Telephone: +1 949 367-9600
Address: 229 Avenida Fabricante, San Clemente 92672, CA, US
Number of employees: 600
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
All rights reserved. Financial Market Data powered by Quotemedia.com. All rights reserved. View the Terms of Use. CBOE BZX (BATS) real-time data for Premium users, NYSE/NYSE MKT (AMEX) data delayed 20 minutes. NASDAQ and other data delayed 15 minutes unless otherwise indicated. Technology and data provided by TeleTrader. Conditions of Use. The regulations of the respective stock are to be observed. Copyright © 2021. All market data is provided by Barchart Solutions. Futures: at least a 10 minute delay. Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. To see all exchange delays and terms of use, please see disclaimer. The Cryptocurrency Market real-time data provided by Cryptocompare.com
Don´t have an account? Register
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.